EMA Issues Second Negative Opinion on Omeros’ Narsoplimab Application
The European Medicines Agency issued a negative opinion on Omeros’ marketing application for narsoplimab, its treatment for stem cell transplant-associated complications. The decision marks the second negative opinion in four months.
Omeros Corporation (OMER) drew investor attention on Friday after the European Medicines Agency (EMA) issued a negative opinion on its marketing application for a treatment for complications associated with stem cell transplants. This was the agency’s second negative opinion in four months. OMER shares were down 4.8% in…